Great catch Xena...we want them IN the tent. Dr. M. was VERY low key when he mentioned their work. Small Bio CEO just don't pass up that kind of opportunity unless they are on a much bigger mission, IMO.
Xena, it becomes a whole new ballgame if Biogen wants to use 2-73 on patients in a P2 trial. I doubt the MTA with Biogen covers that aspect as the limitation of Biogen's work was in the lab, per the PR.
With your thoughts in mind, BIO 2017 has become more interesting to me.
News 
Market Data 
Discover 
